MGLL and migraine disorder: Notably, several recent Phase I clinical trials for the MAGL inhibitor ABX-1431 have shown promise in treating multiple neuropathic and pain-related disorders, including post herpetic neuralgia, diabetic peripheral neuropathy, and post-traumatic neuralgia though its clinical effects for migraine and headache have yet to be tested (30).